Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate® (tiratricol)

Our lead product candidate

Pipeline

Corporate presentation

Press Releases

December 18, 2024

Egetis highlights the positive CHMP opinion for Emcitate®, recent major milestones, and gives a corporate update at Investor Day in Stockholm today

Read more

Regulatory

December 16, 2024

Issuance and repurchase of class C shares for incentive programs

Read more

Regulatory

December 12, 2024

Egetis receives positive CHMP opinion for Emcitate® (tiratricol) for the treatment of MCT8 deficiency

Read more

Upcoming event

December 18, 2024 at 3:00-6:00 pm CET

Egetis Investor Day (Stockholm & online)

Latest presentation

November 8, 2024

Webcast Q3 Report 2024

Latest Report

November 8, 2024

Interim report Q3 2024

Calendar and upcoming reports

December 18, 2024

Investor Day (Stockholm & online)

February 26, 2025

Year-end Report Q4 2024 (7:00am CET)

April 30, 2025

Interim Report Q1 2025 (7:00am CEST)

May 6, 2025

Annual General Meeting

Joshua’s Story

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]